The deferral of Merck's (Merck & Co., Inc.) milestone
payment for its allergy immunotherapy tablet into 2014 from 2013 is largely
offset by a stronger than expected improvement in ALK's underlying
profitability. Hence, revenue is now expected at DKK2.2 billion-DKK2.25 billion
(previously: over DKK2.3 billion) and Ebitda before special items at
approximately DKK250 million (previously: DKK200 million-DKK300 million including
the deferred milestone payment).
The simplification of the production and business structures
is expected to entail full-year restructuring costs of approximately DKK20
million, DKK7 million of which have already been recognised. Read more.
No comments:
Post a Comment